These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 19805356)
1. IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas. Moore LM; Holmes KM; Smith SM; Wu Y; Tchougounova E; Uhrbom L; Sawaya R; Bruner JM; Fuller GN; Zhang W Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16675-9. PubMed ID: 19805356 [TBL] [Abstract][Full Text] [Related]
2. Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Tchougounova E; Kastemar M; Bråsäter D; Holland EC; Westermark B; Uhrbom L Oncogene; 2007 Sep; 26(43):6289-96. PubMed ID: 17438529 [TBL] [Abstract][Full Text] [Related]
3. Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Robinson JP; VanBrocklin MW; Guilbeault AR; Signorelli DL; Brandner S; Holmen SL Oncogene; 2010 Jan; 29(3):335-44. PubMed ID: 19855433 [TBL] [Abstract][Full Text] [Related]
6. Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. Robinson JP; Vanbrocklin MW; Lastwika KJ; McKinney AJ; Brandner S; Holmen SL Oncogene; 2011 Mar; 30(11):1341-50. PubMed ID: 21057530 [TBL] [Abstract][Full Text] [Related]
7. Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas. Labuhn M; Jones G; Speel EJ; Maier D; Zweifel C; Gratzl O; Van Meir EG; Hegi ME; Merlo A Oncogene; 2001 Mar; 20(9):1103-9. PubMed ID: 11314047 [TBL] [Abstract][Full Text] [Related]
8. Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies. Phillips LM; Zhou X; Cogdell DE; Chua CY; Huisinga A; R Hess K; Fuller GN; Zhang W J Pathol; 2016 Jul; 239(3):355-64. PubMed ID: 27125842 [TBL] [Abstract][Full Text] [Related]
9. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Uhrbom L; Dai C; Celestino JC; Rosenblum MK; Fuller GN; Holland EC Cancer Res; 2002 Oct; 62(19):5551-8. PubMed ID: 12359767 [TBL] [Abstract][Full Text] [Related]
10. Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc. Kim HS; Woolard K; Lai C; Bauer PO; Maric D; Song H; Li A; Kotliarova S; Zhang W; Fine HA Cancer Res; 2012 Nov; 72(22):6065-75. PubMed ID: 22986743 [TBL] [Abstract][Full Text] [Related]
11. Sox5 can suppress platelet-derived growth factor B-induced glioma development in Ink4a-deficient mice through induction of acute cellular senescence. Tchougounova E; Jiang Y; Bråsäter D; Lindberg N; Kastemar M; Asplund A; Westermark B; Uhrbom L Oncogene; 2009 Mar; 28(12):1537-48. PubMed ID: 19219070 [TBL] [Abstract][Full Text] [Related]
12. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594 [TBL] [Abstract][Full Text] [Related]
13. Spontaneous canine gliomas: overexpression of EGFR, PDGFRalpha and IGFBP2 demonstrated by tissue microarray immunophenotyping. Higgins RJ; Dickinson PJ; LeCouteur RA; Bollen AW; Wang H; Wang H; Corely LJ; Moore LM; Zang W; Fuller GN J Neurooncol; 2010 May; 98(1):49-55. PubMed ID: 19967449 [TBL] [Abstract][Full Text] [Related]
14. Sox10 has a broad expression pattern in gliomas and enhances platelet-derived growth factor-B--induced gliomagenesis. Ferletta M; Uhrbom L; Olofsson T; Pontén F; Westermark B Mol Cancer Res; 2007 Sep; 5(9):891-7. PubMed ID: 17855658 [TBL] [Abstract][Full Text] [Related]
15. Driver or passenger effects of augmented c-Myc and Cdc20 in gliomagenesis. Ji P; Zhou X; Liu Q; Fuller GN; Phillips LM; Zhang W Oncotarget; 2016 Apr; 7(17):23521-9. PubMed ID: 26993778 [TBL] [Abstract][Full Text] [Related]
16. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Bruggeman SW; Hulsman D; Tanger E; Buckle T; Blom M; Zevenhoven J; van Tellingen O; van Lohuizen M Cancer Cell; 2007 Oct; 12(4):328-41. PubMed ID: 17936558 [TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Dunlap SM; Celestino J; Wang H; Jiang R; Holland EC; Fuller GN; Zhang W Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11736-41. PubMed ID: 17606927 [TBL] [Abstract][Full Text] [Related]
18. Specific Deletion of p16 Ishida K; Tomita H; Kanayama T; Noguchi K; Niwa A; Kawaguchi M; Miyai M; Matsuo M; Imaizumi Y; Kato K; Hatano Y; Hirata A; Okada H; Shibata T; Hara A Am J Pathol; 2020 Jun; 190(6):1332-1342. PubMed ID: 32194051 [TBL] [Abstract][Full Text] [Related]
19. The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. D'Amico M; Wu K; Di Vizio D; Reutens AT; Stahl M; Fu M; Albanese C; Russell RG; Muller WJ; White M; Negassa A; Lee HW; DePinho RA; Pestell RG Cancer Res; 2003 Jun; 63(12):3395-402. PubMed ID: 12810676 [TBL] [Abstract][Full Text] [Related]